Your session is about to expire
← Back to Search
Chemotherapy for Lung Cancer
Study Summary
This trial is testing a new technique for delivering chemotherapy directly into the lungs at the time of surgery. The goal is to kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the body from the side effects of chemotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 854 Patients • NCT00003389Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am under 65 years old.I have three or more spots on my lungs.Your heart's pumping ability is less than 50%.I can take care of myself and am up and about more than half of the day.My cancer has spread to both lungs.I have received over 450 mg of doxorubicin.I have had surgery to remove lung metastases.My cancer on the opposite side can be treated with surgery or radiation.I have a history of serious lung disease or inflammation.I have been diagnosed with soft tissue or bone cancer.All my lung cancer spots can be removed with specific surgery.I am either 65 years or older, or younger than 18.My cancer has not spread beyond my lungs.You are allergic to doxorubicin.
- Group 1: Doxorubicin 5 mcg/ml
- Group 2: Doxorubicin 7 mcg/ml
- Group 3: Doxorubicin 9 mcg/ml
- Group 4: Doxorubicin 7 mcg/ml - expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the Food and Drug Administration sanctioned Doxorubicin for therapeutic use?
"Due to a lack of data regarding safety and efficacy, our team at Power assigned Doxorubicin an initial score of 1."
Does the age criteria for this clinical experiment encompass those who are octogenarians or older?
"This medical trial is restricted to those ages 0-64. Conversely, 309 trials are currently available for minors and 2680 exist for seniors over the age of 65."
Is registration still available for this investigation?
"Clinicaltrials.gov reveals that this medical trial is not accepting new participants at the moment. The study was initially listed on February 1st 2016 and its page last modified on April 8th 2022. Although this test is closed to enrollment, there are 2863 other studies looking for volunteers presently."
Are there any documented precedents of experiments that use Doxorubicin?
"Currently, 360 clinical trials are being conducted to test the efficacy of Doxorubicin. Of these, 119 are in their final phase and primarily based in New york City; however, there are over 23000 sites gathering data from around the country."
To what demographic is this research project accessible?
"This specific clinical trial is recruiting 11 patients, aged 0 to 64 years old with sarcoma of the bone. As per inclusion criteria, they must have an ECOG score between 0 and 2, 3 or more lesions in their lungs accessible for treatment using IVLP (the remaining ones should be treated by surgery/radiation 4-12 weeks before commencing IVLP), be under 65 years old and present contralateral disease amenable to either radiation therapy or surgical resection."
To what extent is the capacity of this experiment being tested?
"At this time, this trial is not enrolling any additional participants. The study was posted on the 1st of February 2016 and last updated on April 8th 2022. If you are looking for other medical trials, there are presently 2503 studies with sarcoma-related research pursues that require volunteers as well as 360 clinical investigations concerning Doxorubicin which are actively recruiting patients."
What ailments is Doxorubicin primarily employed to address?
"Doxorubicin is commonly used as a form of therapy for lymphoma and Hodgkin's Disease. Additionally, it can be employed to treat conditions such as bronchogenic carcinoma, neuroblastoma (NB), and Sezary Syndrome."
Has a similar clinical trial been conducted in the past?
"Since its first trial in 1997, sponsored by Alfacell and involving 300 patients, doxorubicin has been studied extensively. Subsequently granted Phase 3 approval for use as a drug, 360 different trials are currently active across 1941 cities and 66 countries worldwide."
Share this study with friends
Copy Link
Messenger